Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Accenture
Teva
Healthtrust
Cantor Fitzgerald
Cerilliant
Queensland Health
Covington
US Army

Generated: July 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202292

« Back to Dashboard

NDA 202292 describes MYTESI, which is a drug marketed by Napo Pharms Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the MYTESI profile page.

The generic ingredient in MYTESI is crofelemer. One supplier is listed for this compound. Additional details are available on the crofelemer profile page.
Summary for 202292
Tradename:MYTESI
Applicant:Napo Pharms Inc
Ingredient:crofelemer
Patents:5
Pharmacology for NDA: 202292
Suppliers and Packaging for NDA: 202292
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292 NDA Napo Pharmaceuticals, Inc. 70564-802 N 70564-802-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength125MG
Approval Date:Dec 31, 2012TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jun 7, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jun 16, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
Patent:➤ Try a Free TrialPatent Expiration:Jan 11, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

Expired US Patents for NDA 202292

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fuji
Cerilliant
Colorcon
Queensland Health
Argus Health
Chubb
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.